Appendix B
Public Meeting Agenda March 11, 2002

Immunization Safety Review Committee

Hepatitis B Vaccine and Neurological Disorders

Foundry Building, Room 2004

Washington, DC

8:30–8:45 am

Welcome and Introduction

Marie McCormick, MD, ScD

Committee Chair

8:45–9:00 am

Clinical Description and Diagnosis of Multiple Sclerosis

Emmanuelle Waubant, MD

University of California, San Francisco Multiple Sclerosis Center

(co-author of commissioned paper posted on IOM website)

9:00–9:30 am

Pharmacovigilance and Case-Control Study of Hepatitis B Vaccine and Multiple Sclerosis

Bernard Begaud, MD, PhD (Presented via conference call)

Annie Fourrier, PharmD, MPH (Presented via conference call)

Universite Victor Segalen Bordeaux, France

9:30–10:15 am

Risk of Multiple Sclerosis Relapse After Immunization: European Database for Multiple Sclerosis



The National Academies | 500 Fifth St. N.W. | Washington, D.C. 20001
Copyright © National Academy of Sciences. All rights reserved.
Terms of Use and Privacy Statement



Below are the first 10 and last 10 pages of uncorrected machine-read text (when available) of this chapter, followed by the top 30 algorithmically extracted key phrases from the chapter as a whole.
Intended to provide our own search engines and external engines with highly rich, chapter-representative searchable text on the opening pages of each chapter. Because it is UNCORRECTED material, please consider the following text as a useful but insufficient proxy for the authoritative book pages.

Do not use for reproduction, copying, pasting, or reading; exclusively for search engines.

OCR for page 100
Immunization Safety Review: Hepatitis B Vaccine and Demyelinating Neurological Disorders Appendix B Public Meeting Agenda March 11, 2002 Immunization Safety Review Committee Hepatitis B Vaccine and Neurological Disorders Foundry Building, Room 2004 Washington, DC 8:30–8:45 am Welcome and Introduction Marie McCormick, MD, ScD Committee Chair 8:45–9:00 am Clinical Description and Diagnosis of Multiple Sclerosis Emmanuelle Waubant, MD University of California, San Francisco Multiple Sclerosis Center (co-author of commissioned paper posted on IOM website) 9:00–9:30 am Pharmacovigilance and Case-Control Study of Hepatitis B Vaccine and Multiple Sclerosis Bernard Begaud, MD, PhD (Presented via conference call) Annie Fourrier, PharmD, MPH (Presented via conference call) Universite Victor Segalen Bordeaux, France 9:30–10:15 am Risk of Multiple Sclerosis Relapse After Immunization: European Database for Multiple Sclerosis

OCR for page 100
Immunization Safety Review: Hepatitis B Vaccine and Demyelinating Neurological Disorders   Samy Suissa, PhD McGill University 10:15–10:30 am Break 10:30–11:15 am Risk of Multiple Sclerosis After Hepatitis B Immunization: The Nurses’ Health Study Alberto Ascherio, MD, DrPH Harvard University 11:15 am–12:00 pm Risk of Demyelinating Disease After Hepatitis B Vaccination: The Vaccine Safety Datalink Frank DeStefano, MD, MPH Centers for Disease Control and Prevention 12:00 pm–1:00 pm Lunch 1:00–1:45 pm Possible Mechanisms for Hepatitis B Vaccine-Induced Multiple Sclerosis and Other Demyelinating Diseases Emmanuelle Waubant, MD University of California, San Francisco Multiple Sclerosis Center (co-author of commissioned paper posted on IOM website) 1:45–2:30 pm Recommendations for Newborn and Infant Hepatitis B Vaccination Historical Perspective Neal Halsey, MD Johns Hopkins University Recent Analyses of Hepatitis B Viral Infections in Children Eric Mast, MD National Center for Infectious Diseases Centers for Disease Control and Prevention

OCR for page 100
Immunization Safety Review: Hepatitis B Vaccine and Demyelinating Neurological Disorders 2:30–3:15 pm Update on Communications Activities, National Immunization Program, Centers for Disease Control and Prevention Glen Nowak, PhD Centers for Disease Control and Prevention 3:15–4:00 pm Public Comment Session and Discussion 4:00 pm Adjourn